Literature DB >> 31952070

Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.

Radhika Chadha1, James H Meador-Woodruff2.   

Abstract

Abnormal neurotransmission is central to schizophrenia (SZ). Alterations across multiple neurotransmitter systems in SZ suggest that this illness may be associated with dysregulation of core intracellular processes such as signaling pathways that underlie the regulation and integration of these systems. The AKT-mTOR signaling cascade has been implicated in SZ by gene association, postmortem brain and animal studies. AKT and mTOR are serine/threonine kinases which play important roles in cell growth, proliferation, survival, and differentiation. Both AKT and mTOR require phosphorylation at specific sites for their complete activation. mTOR forms two functionally distinct multiprotein complexes, mTOR Complex 1 (mTORC1) and Complex 2 (mTORC2). mTORC1 mediates ribosome biogenesis, protein translation, and autophagy, whereas mTORC2 contributes to actin dynamics. Altered protein synthesis and actin dynamics can lead to an abnormal neuronal morphology resulting in deficits in learning and memory. Currently, there is a lack of direct evidence to support the hypothesis of disrupted mTOR signaling in SZ, and we have addressed this by characterizing this signaling pathway in SZ brain. We found a reduction in AKT and mTOR protein expression and/or phosphorylation state in dorsolateral prefrontal cortex (DLPFC) from 22 pairs of SZ and matched comparison subjects. We also found reduced protein expression of GβL, a subunit protein common to both mTOR complexes. We further investigated mTOR complex-specific subunit composition and phosphorylation state, and found abnormal mTOR expression in both complexes in SZ DLPFC. These findings provide evidence that proteins associated with the AKT-mTOR signaling cascade are downregulated in SZ DLPFC.

Entities:  

Year:  2020        PMID: 31952070      PMCID: PMC7162985          DOI: 10.1038/s41386-020-0614-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

Review 1.  The possible role of the Akt signaling pathway in schizophrenia.

Authors:  Wenhua Zheng; Haitao Wang; Zhiwen Zeng; Jun Lin; Peter J Little; Lalit K Srivastava; Remi Quirion
Journal:  Brain Res       Date:  2012-07-04       Impact factor: 3.252

Review 2.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 3.  Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia.

Authors:  J N Joyce; J H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  1997-06       Impact factor: 7.853

4.  Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia.

Authors:  Adam J Funk; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

5.  Mechanism for long-term memory formation when synaptic strengthening is impaired.

Authors:  Kasia Radwanska; Nikolay I Medvedev; Grace S Pereira; Olivia Engmann; Nina Thiede; Marcio F D Moraes; Agnes Villers; Elaine E Irvine; Nicollette S Maunganidze; Elżbieta M Pyza; Laurence Ris; Magda Szymańska; Michał Lipiński; Leszek Kaczmarek; Michael G Stewart; K Peter Giese
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 6.  Molecular mechanisms of schizophrenia.

Authors:  Undine E Lang; Imke Puls; Daniel J Muller; Nathalie Strutz-Seebohm; Jurgen Gallinat
Journal:  Cell Physiol Biochem       Date:  2007

7.  AKT/GSK3 signaling pathway and schizophrenia.

Authors:  Effat S Emamian
Journal:  Front Mol Neurosci       Date:  2012-03-15       Impact factor: 5.639

8.  Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses.

Authors:  Yasuko Kitagishi; Mayumi Kobayashi; Kanae Kikuta; Satoru Matsuda
Journal:  Depress Res Treat       Date:  2012-12-18

Review 9.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

10.  Abnormalities of signal transduction networks in chronic schizophrenia.

Authors:  Jennifer L McGuire; Erica A Depasquale; Adam J Funk; Sinead M O'Donnovan; Kathryn Hasselfeld; Shruti Marwaha; John H Hammond; Vahram Hartounian; James H Meador-Woodruff; Jarek Meller; Robert E McCullumsmith
Journal:  NPJ Schizophr       Date:  2017-09-12
View more
  15 in total

1.  Anxiety and cognitive-related effects of Δ 9-tetrahydrocannabinol (THC) are differentially mediated through distinct GSK-3 vs. Akt-mTOR pathways in the nucleus accumbens of male rats.

Authors:  Roger Hudson; Christopher Norris; Hanna J Szkudlarek; Dinat Khan; Susanne Schmid; Walter J Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2021-12-03       Impact factor: 4.530

2.  GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.

Authors:  Petros Petrikis; Alexandra Polyzou; Kyriaki Premeti; Argyro Roumelioti; Andreas Karampas; Georgios Georgiou; Dionysios Grigoriadis; George Leondaritis
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

Review 3.  Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes.

Authors:  Jacopo Sapienza; Marta Bosia; Marco Spangaro; Francesca Martini; Giulia Agostoni; Federica Cuoco; Federica Cocchi; Roberto Cavallaro
Journal:  Mol Psychiatry       Date:  2022-08-05       Impact factor: 13.437

4.  S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission.

Authors:  Linlu Tian; Yongxia Wu; Hee-Jin Choi; Xiaohui Sui; Xinlei Li; M Hanief Sofi; Mohamed Faisal Kassir; Xiao Chen; Shikhar Mehrotra; Besim Ogretmen; Xue-Zhong Yu
Journal:  Cell Mol Immunol       Date:  2022-09-08       Impact factor: 22.096

Review 5.  Exosomes in schizophrenia: Pathophysiological mechanisms, biomarkers, and therapeutic targets.

Authors:  Yu Wang; Nousayhah Amdanee; Xiangrong Zhang
Journal:  Eur Psychiatry       Date:  2022-09-09       Impact factor: 7.156

6.  PTMs: A Missing Piece for Schizophrenia Studies.

Authors:  Caroline Brandão-Teles; Bradley J Smith; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Effects of Risperidone and Prenatal Poly I:C Exposure on GABAA Receptors and AKT-GSK3β Pathway in the Ventral Tegmental Area of Female Juvenile Rats.

Authors:  Shiyan Chen; Jiamei Lian; Yueqing Su; Chao Deng
Journal:  Biomolecules       Date:  2022-05-23

Review 8.  The stress-Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches.

Authors:  Cristine Marie Yde Ohki; Leoni Grossmann; Emma Alber; Tanushree Dwivedi; Gregor Berger; Anna Maria Werling; Susanne Walitza; Edna Grünblatt
Journal:  Transl Psychiatry       Date:  2020-09-18       Impact factor: 6.222

Review 9.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

10.  Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia.

Authors:  Inés Ibarra-Lecue; Rebeca Diez-Alarcia; Benito Morentin; J Javier Meana; Luis F Callado; Leyre Urigüen
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.